Transenterix Inc (NYSEAMERICAN:TRXC) reported that the firm has obtained FDA 510(k) approval for the Senhance™ Surgical Robotic System. Todd M. Pope, the CEO and President, expressed that the clearance of the Senhance System in the United States is a milestone in the advancement of robotics and is anticipated to deliver improvement in the value, efficacy and choices provided to patients, hospitals and surgeons.
Millions of surgical procedures in the United States are done each year laparoscopically with basic manual equipments that limit surgeons’ capability, control and comfort. New choices are required that enhance the control, comfort and senses of the surgeon, lower the invasiveness of surgery for the patient, and increase value for the hospital. This marks Senhance as the new choice for the market.
The details
With this approval, the Senhance turns into the preliminary new market entrant into the segment of abdominal surgical robotics since 2000. Utilizing the system, a surgeon directs a camera and small surgical instruments with comfort and precise movements. The system builds on the base of laparoscopy and showcases the security of haptic response and eye-sensing camera control for the preliminary time in a robotic surgery platform.
In addition, the Senhance uses an open architecture, which enables surgeons and hospitals to use current technology investments within the working room ecosystem. The system is particularly advanced to manage operative costs effectively, turning robotic surgery cost-effective on a per-process basis via the application of fully reusable instruments.
Dr. Steve Eubanks expressed that surgeons are approaching the limits of minimally invasive care done with handheld manual instruments as well as cameras, and are looking for new technologies that will enable them to go beyond these boundaries. The future will be led by the appropriate use of information tools and robotics in the operating room. Latest Senhance platform provides laparoscopic surgeons robotic precision, haptic feedback and control of their vision while lowering procedural costs.
